Palatin Technologies, Inc. (PTN)

Market Cap	38.99M +108.5%
Revenue (ttm)	8.96M +2,461.0%
Net Income	-9.63M
EPS	-7.93
Shares Out	1.77M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,935
Open	20.56
Previous Close	20.96
Day's Range	19.40 - 20.93
52-Week Range	1.75 - 49.50
Beta	-0.20
Analysts	Strong Buy
Price Target	60.00 (+197.69%)
Earnings Date	Feb 17, 2026

About PTN

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company als...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 28, 1993
• Employees: 29
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: PTN
• Website: https://palatin.com

Analyst Summary

According to one analyst, the rating for PTN stock is "Strong Buy" and the 12-month stock price target is $60.0.

Price Target

$60.0

(197.69% upside)

Analyst Consensus: Strong Buy